Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Abbvie Inc ABBV

Alternate Symbol(s):  N.ABBV

AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics... see more
< Previous
Next >

Current News (NYSE:ABBV)

INVESTOR ALERT: Weiss Law Investigates ImmunoGen, Inc.

Accesswire 3 days ago

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

PR Newswire 4 days ago

AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)

PR Newswire 5 days ago

AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

PR Newswire 7 days ago

Fifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever

PR Newswire November 20, 2023

Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine

PR Newswire November 16, 2023

NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year

GlobeNewswire November 13, 2023

Natrelle® Unveils New "For Every BODY" Campaign

PR Newswire November 8, 2023

Roundhill Investments Launches Dividend Monarchs ETF (NYSE Arca: KNGS)

PR Newswire November 2, 2023

Bullboard Posts (NYSE:ABBV)

Incredible Value. ENTG at about 25% of One Years Revenue

.with revenues now demonstrating an upward Trajectory amd likely attaining profitability within a couple of quarters. May reportage for...
Wrywisdom - August 10, 2022


India's Ivermectin Blackout - Part V: The Secret Revealed ...   Sep 27, 2021 · By September 12, 2021...
zeropointenergy - October 6, 2021

what was the big drop ?? saw no news

what was the big drop ?? saw no news
plomar2011 - September 1, 2021

Multiple Sclerosis Therapies Market Industry Growth 2026

According to IMARC Group’s latest report, titled “Multiple Sclerosis Therapies Market: Global Industry Trends, Share, Size, Growth...
edwardebreen15 - August 2, 2021

Bonvoyage12....Lying Pumper

Ignore this clown as he posts lies trying to mislead investors about the actual state of the company...he also posts this same BS on...
Mil_Man54 - December 26, 2020


<< View Post To Watch Video >> Good progress takes time don't be fooled by short sellers trying to talk bad points...
MagnetSauce - September 18, 2020